TENKASI

This brand name is authorized in Austria, Estonia, Finland, France, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom

Active ingredients

The drug TENKASI contains one active pharmaceutical ingredient (API):

1 Oritavancin
UNII PUG62FRZ2E - ORITAVANCIN

Oritavancin is used for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI).

Read about Oritavancin

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
TENKASI Powder for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J01XA05 J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01X Other antibacterials → J01XA Glycopeptide antibacterials
Discover more medicines within J01XA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1680960, 3044113
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 433794
Country: FR Base de données publique des médicaments Identifier(s): 67623773, 68529070
Country: IT Agenzia del Farmaco Identifier(s): 044015016, 044015028
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1076035
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100342536

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.